Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI0002h in Relapsed/Refractory Multiple Myeloma
NCT04309981Phase 2Unknown
- Start
- May 2020
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI0002h in multiple myeloma (MM). Primary endpoints: Overall Response Rate at 3 months and Cytokine Release Syndrome Rate at 30 days. Status: unknown.
02
Drugs
ARI0002h
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04309981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309981.